

# John A Carter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1695925/publications.pdf>

Version: 2024-02-01

30  
papers

520  
citations

687363

13  
h-index

677142

22  
g-index

32  
all docs

32  
docs citations

32  
times ranked

844  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?. Orphanet Journal of Rare Diseases, 2022, 17, 157.	2.7	8
2	Budget Impact and Cost-Effectiveness of Intravenous Meloxicam to Treat Moderateâ€“Severe Postoperative Pain. Advances in Therapy, 2022, 39, 3524-3538.	2.9	1
3	Corneal cross-linking versus conventional management for keratoconus: a lifetime economic model. Journal of Medical Economics, 2021, 24, 410-420.	2.1	14
4	Efficacy of non-opioid analgesics to control postoperative pain: a network meta-analysis. BMC Anesthesiology, 2020, 20, 272.	1.8	10
5	Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy. Neurology and Therapy, 2020, 9, 135-149.	3.2	3
6	Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series. Orphanet Journal of Rare Diseases, 2019, 14, 34.	2.7	38
7	Patient versus neurologist preferences: A discrete choice experiment for antiepileptic drug therapies. Epilepsy and Behavior, 2018, 80, 247-253.	1.7	17
8	Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle and Nerve, 2018, 57, 829-837.	2.2	121
9	Meta-Analysis of Caregiver-Directed Psychosocial Interventions for Schizophrenia. Community Mental Health Journal, 2018, 54, 983-991.	2.0	19
10	Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 111-112.	3.0	9
11	Epidemiological and clinical characteristics of persons with transthyretin hereditary amyloid polyneuropathy: a global synthesis of 532 cases. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 109-110.	3.0	10
12	Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder. Journal of Medical Economics, 2017, 20, 893-901.	2.1	15
13	Estimating Population-Level Prevalence of Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy. Journal of Cardiac Failure, 2017, 23, S73.	1.7	3
14	Qualitative modification and development of patient- and caregiver-reported outcome measures for iron chelation therapy. Health and Quality of Life Outcomes, 2017, 15, 129.	2.4	0
15	Substitution Therapy With Flexible-Dose Depot Buprenorphine Injection To Treat Opioid Use Disorder In The United Kingdom: A Pharmacoeconomic Assessment. Value in Health, 2017, 20, A711.	0.3	1
16	The impact of second-line agents on patientsâ€™ health-related quality of life in the treatment for non-small cell lung cancer: a systematic review. Quality of Life Research, 2013, 22, 1015-1026.	3.1	13
17	Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 483-496.	1.4	12
18	Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A cost-effectiveness analysis. Journal of Medical Economics, 2013, 16, 19-29.	2.1	38

#	ARTICLE	IF	CITATIONS
19	Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 335-343.	1.4	32
20	Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. Journal of Medical Economics, 2012, 15, 1054-1063.	2.1	44
21	Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 425-437.	1.4	17
22	Pharmacoeconomics of Bisphosphonates for Skeletal-Related Event Prevention in Metastatic Non-Breast Solid Tumours. Pharmacoeconomics, 2012, 30, 373-386.	3.3	6
23	PCN66 Cost-Effectiveness of Denosumab Versus Zoledronic Acid for Skeletal-Related Event (SRE) Reduction in Bone-Metastatic Prostate Cancer (mPC) in the UK. Value in Health, 2012, 15, A420-A421.	0.3	0
24	Estimating Preference-Based EQ-5D Health State Utilities or Item Responses from Neuropathic Pain Scores. Patient, 2012, 5, 185-197.	2.7	8
25	Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Management of Skeletal Metastases Secondary to Breast Cancer. Clinical Therapeutics, 2012, 34, 1334-1349.	2.5	27
26	Estimating Preference-Based EQ-5D Health State Utilities or Item Responses from Neuropathic Pain Scores. Patient, 2012, 5, 185-197.	2.7	12
27	PCN73 Cost Effectiveness of Zoledronic Acid vs. Pamidronate or No therapy for the Treatment of Bone Metastases Secondary to Prostate Cancer. Value in Health, 2011, 14, A447.	0.3	0
28	Cost-Effectiveness of Zoledronic Acid in the Management of Skeletal Metastases in Patients With Lung Cancer in France, Germany, Portugal, The Netherlands, and the United Kingdom. Clinical Therapeutics, 2011, 33, 291-304.e8.	2.5	16
29	Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities. Health and Quality of Life Outcomes, 2011, 9, 119.	2.4	16
30	Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands. Journal of Medical Economics, 2011, 14, 288-298.	2.1	10